EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Risk of major congenital anomalies and beta‐blockers: A comparative study from the EFEMERIS database

Laurane Delteil, Thierry Vial, Sophie Gautier, Annie-Pierre Jonville, Jacques Amar, Dominique Masset, Jérôme Massardier, Fatiha Karam, Isabelle Lacroix iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70322 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Laurane Delteil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Réseau Regards, Pharmacologie Médicale Et Clinique, Centre Hospitalier Universitaire De Toulouse, INSERM Cerpop, France. Hauptthemen laut MEDLINE: Adrenergic beta-Antagonists, Abnormalities, Drug-Induced, Calcium Channel Blockers, Antihypertensive Agents. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate if exposure to beta‐blockers during the first trimester of pregnancy increases the risk of congenital anomaly.

Methods

An observational comparative study was carried out. This study was conducted using EFEMERIS, a medico‐administrative database. We included women who had a pregnancy between 2004 and 2021 registered in EFEMERIS. Comparison of women receiving beta‐blockers during the first trimester of pregnancy with those receiving calcium channel blockers and with women unexposed to antihypertensive medications. Logistic regression models adjusted for relevant confounders were used to estimate the adjusted odds ratios (ORa) for major congenital anomalies. We calculated the ajusted Odds Ratio (ORa) and its 95% confidence intervals (CI) for major congenital anomalies.

Results

Data from 1813 pregnant women (1%) exposed to beta‐blockers, 2903 (1.6%) exposed to calcium channel blockers and 172 284 unexposed to any antihypertensive medication were compared. Multivariate analyses showed a statistically significant increased risk of major congenital anomalies in fetuses/children exposed to beta‐blockers (ORa[95% CI] = 1.56 [1.07–2.18]) compared with unexposed group. However, this increased risk was not observed when comparing with women exposed to calcium channel blockers (ORa[95% CI] = 0.71 [0.29–2.15]). An increased risk of major congenital anomalies was also observed in fetuses/children exposed to labetalol compared with those unexposed to antihypertensive medications (ORa [95% CI] = 2.00 [1.06–3.40]), but not when compared with those exposed to calcium channel blockers (ORa [95% CI] = 1.06 [0.37–3.48]).

Conclusions

This study found no increased risk of major congenital anomalies in women exposed to beta‐blockers compared with those exposed to calcium channel blockers in early pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenergic beta-AntagonistsAbnormalities, Drug-InducedCalcium Channel BlockersAntihypertensive AgentsHumansFemalePregnancyAdultDatabases, FactualPregnancy Trimester, FirstYoung AdultRisk FactorsInfant, Newborn

Stichwörter der Autor:innen

antihypertensive medicationsbeta‐blockerscongenital anomalylabetalolpregnancy

Substanzen

Adrenergic beta-AntagonistsCalcium Channel BlockersAntihypertensive Agents

Autor:innen und Institutionen

  • Réseau Regards, Pharmacologie Médicale Et Clinique, Centre Hospitalier Universitaire De Toulouse, INSERM Cerpop, France.
  • Centre Régional de Pharmacovigilance, Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices civils de Lyon, Lyon, France.
  • Centre Régional de Pharmacovigilance Nord Pas de Calais, service hospitalo-universitaire de pharmacologie médicale, CHU de Lille, France.
  • Centre Régional de Pharmacovigilance Centre Val de Loire, Service de PHarmacosurveillance, CHU de Tours, France.
  • Service d'hypertension artérielle, CHU de Toulouse, France.
  • Agence Nationale de Sécurité des produits de Santé (ANSM), Paris, France.

ORCID-Profile: Isabelle Lacroix

Förderung

  • Agence Nationale de Sécurité du Médicament et des Produits de Santé

Zitieren

APA

Delteil, L., Vial, T., Gautier, S., Jonville, A. P., Amar, J., Masset, D., Massardier, J., Karam, F., & Lacroix, I. (2025). Risk of major congenital anomalies and beta‐blockers: A comparative study from the EFEMERIS database. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70322

Vancouver

Delteil L, Vial T, Gautier S, Jonville AP, Amar J, Masset D, et al. Risk of major congenital anomalies and beta‐blockers: A comparative study from the EFEMERIS database. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70322

BibTeX
@article{Delteil2025,
  author = {Delteil, Laurane and Vial, Thierry and Gautier, Sophie and Jonville, Annie-Pierre and Amar, Jacques and Masset, Dominique and Massardier, Jérôme and Karam, Fatiha and Lacroix, Isabelle},
  title = {Risk of major congenital anomalies and beta‐blockers: A comparative study from the EFEMERIS database},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70322}
}
Kostenlos starten →